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Aim: Carers may offer valuable insight into the true health status of patients with 
rheumatoid arthritis (RA). This multinational, multi-stakeholder, exploratory study in 
Australia, China and Japan aimed to enrich our understanding of the role and poten-
tial impact of carers on RA management.
Method: This study used a 2-phase sequential mixed methods approach involving 
3 key stakeholder groups: rheumatologists, RA patients and carers. The first phase 
involved an in-depth qualitative exploratory survey (n = 30), which informed the de-
velopment of the subsequent quantitative validation survey (n = 908). In both phases, 
patients and carers provided self-assessments of disease and support parameters.
Results: In the qualitative phase, patients usually understated the amount of physical 
support required, compared to carers. Rheumatologists underestimated the amount 
of physical and emotional care required, compared to carers and patients; how-
ever, in the quantitative phase, rheumatologists overestimated the level of support 
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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1  | INTRODUC TION
Effective management of rheumatoid arthritis (RA) requires the co-
ordinated efforts of a multidisciplinary team with the patient as its 
central focus.1 Patient-reported outcomes (PROs) are at the core 
of assessing RA treatment response.2 However, PROs have several 
limitations. To obtain accurate data, patients must be willing to pro-
vide information, and this may be influenced by factors such as the 
length of the questionnaire, patients’ perception of usefulness, and 
anxiety about use of the information provided to limit services.3-5 
Additionally, clinicians’ perceptions of the usefulness of PROs may 
also impact implementation in clinical practice.3,5
For patients with RA, carers may be key to addressing some of 
these limitations. Given their time investment, carers may offer import-
ant insight into the patient's true health status. As first-hand observers, 
carers may provide rheumatologists with a more complete picture of 
the patient's physical and emotional status. They may also help patients 
understand and adhere to their treatments, keep track of their appoint-
ments, follow nutritional guidelines and manage other aspects of life.6,7
The role of carers is complex, and involves providing physical, 
emotional and financial support.6,7 However, studies evaluating their 
role in RA are scarce.8,9 One study in patients with RA found that 
patients were inclined to significantly underscore their level of pain, 
compared with their carers.8 This could affect the rheumatologist's 
decision to adjust the management strategy and undermine efforts 
to achieve optimal results, unless further information is obtained 
from the carer.8 Another study highlighted carers may help to illu-
minate factors that patients may not consider themselves.9 For in-
stance, patients were more likely to consider intensive management 
acceptable if their previous treatments had failed. However, carers 
took into consideration the patient's past experiences of side ef-
fects, treatment duration, and response to current treatment (both 
emotionally and physically).9 This implies carers may provide rheu-
matologists with a more holistic view of the patient's situation.
Current management paradigms for RA tend to neglect the views 
of carers. This regional, multinational, multi-stakeholder, exploratory 
study was conducted to enrich our understanding of the roles and 




We used a sequential mixed methods approach to understand the 
roles of carers and the potential impact of carer involvement. The 
initial qualitative phase used semi-structured interviews to under-
stand the role of carers in RA management. The key themes high-
lighted in this phase informed the development of the quantitative 
validation survey.10 This was a multinational, uni-region study con-
ducted in Australia, China and Japan.
2.2 | Qualitative methods
The phase I survey was conducted between 14 May 2018 and 15 
June 2018. It adopted a qualitative, exploratory approach using 
semi-structured in-depth face-to-face interviews with carers, pa-
tients and rheumatologists. Recruitment across China, Japan and 
Australia consisted of triads of treating rheumatologists, patients 
living with RA, and their carers. Rheumatologist eligibility criteria 
included: aged 30-65 years; currently registered and practicing; 
registered for ≥2 years; and currently treating RA patients of mild, 
moderate and severe conditions. Patients were eligible to participate 
if they were: aged >18 years; and self-assessed as mild, moderate or 
severe RA during recruitment. RA severity for research recruitment 
categorization was based on the patients’ self-reported definition. 
Carer eligibility criteria included: aged >18 years; and had been a 
carer for ≥6 months (to include influencing treatment and care de-
cision-making or providing direct assistance for ≥4 hours per day). 
Interview topics included: (a) RA patient journey and experiences, 
highs and lows; (b) role and importance of carers; (c) met and unmet 
needs; (d) treatment decisions; (e) adherence; (f) improving patient 
provided by carers. Levels of support provided by carers increased as disease sever-
ity increased. Active participation of carers in clinical consultations and treatment 
decision-making was deemed important by 55% of all patients and 82% of all carers. 
All stakeholders believed carers’ insights into the physical and emotional conditions 
of patients were useful and should be considered in clinical decision-making. Over 
95% of rheumatologists reported soliciting input from the carer.
Conclusion: Carers provide valuable input that can give clinicians greater insight into 
the patients’ physical and emotional states, and treatment adherence. Development of 
standardized carer-reported outcomes that correlate with patient-reported outcomes 
and clinical parameters will ensure clinical meaningfulness and external validity.
K E Y W O R D S
carer reported, holistic, patient centred, qualitative
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outcomes; (g) supporting carers; and (h) improving care of the pa-
tient. Thematic analysis was used to extract recurring themes.
2.3 | Stakeholder insight
On 19 July 2018, a panel of experts, the “CollAboRatE Coalition”, met 
to provide feedback on the qualitative exploratory study findings, 
provide input on the quantitative validation study and advise on the 
approach to share the research findings and address the insights gen-
erated. CollAboRatE is a regional initiative led by a multi-stakeholder 
coalition of rheumatologists, patient and carer organizations across 
Asia-Pacific which aims to understand and elevate the role of carers in 
the clinical management of RA, empower carers to become involved in 
and contribute to treatment decisions, and build the capacity and influ-
ence of rheumatology carer and patient organizations.
2.4 | Quantitative methods
The phase II survey was conducted between 7 August 2018 and 
21 August 2018. This online validation survey consisted of 3 sep-
arate questionnaires designed specifically for carers, patients and 
rheumatologists. Questionnaires were reverse-translated from 
English to Japanese and simplified Chinese (and responses to 
English) by professional NAATI (National Accreditation Authority 
for Translators and Interpreters) translators. Questionnaires were 
deployed via an online scripted survey approach. Respondents 
were pre-screened via an online screener or telephone screen-
ing. Rheumatologist eligibility criteria included self-identified as 
currently registered for ≥2 years and treating patients with RA. 
Patient eligibility criteria included >18 years of age and self-iden-
tified as being diagnosed with RA. Patients were further classi-
fied based on self-descriptions of severity and disease activity. 
Definitions of severity: mild defined as “I live an active and in-
dependent life most of the time”; moderate defined as “I some-
times require physical support”; and severe defined as “I require 
physical support most of the time”. Definitions of disease activity: 
stable defined as “My symptoms have been well managed for the 
last 3 months”; and progressive defined as “My symptoms have 
been getting worse over the last 3 months”. Carer eligibility crite-
ria included ≥18 years of age and self-identified as being a carer 
of a person with RA. The main carer was defined as the person 
who provides the most physical support to someone, in managing 
their RA condition. Recruitment was not conducted in triads or 
pairs. Carers were asked to describe the current RA condition of 
the person they are caring for (mild, moderate or severe). The final 
data set was tabulated and descriptively analyzed. Responses to 
the same questions from patients, carers and rheumatologists 
were compared and contrasted. A further descriptive analysis 
was conducted to better understand the role of a carer in the 
moderate-to-severe patient subgroup.
2.5 | Ethics approval and consent to participate
No ethics approval was required as this was a quality assurance ac-
tivity, which is in line with the standards and guidelines for ethics 
review in all 3 countries11-13 as well as with the practice of similar 
studies published recently in the area of carers in rheumatology.14-17 
Written informed consent was obtained from all participants in both 
the qualitative and quantitative studies.
3  | RESULTS
3.1 | Qualitative
In total, 30 stakeholders from Australia (n = 12), China (n = 12), and 
Japan (n = 6), participated in the qualitative exploratory survey, 
comprising 10 rheumatologists, 10 patients with RA and 10 carers. 
Each interview was conducted by a different interviewer (30 inter-
viewers). Recruitment consisted of 3 triads (9 participants) com-
posed of treating rheumatologist, patient and carer, and 5 pairs (10 
participants) composed of patient and carer. All other participants 
(7 rheumatologists, 2 patients and 2 carers) were not part of a triad 
or pair.
3.1.1 | Role of the carer
Carers of patients with RA provided physical care, helped with med-
ication and emotional support. Patients with severe RA required 
physical care “daily” while some patients with moderate RA required 
physical care “very often” or “most of the time”. Carers reported 
spending ≥10 hours per week with severe patients and ≥3 hours 
per week with moderate patients, providing physical care, help with 
medication and emotional support.
Patients tended to understate the amount of physical support 
required, compared to carer reports. In contrast, while rheumatol-
ogists acknowledged RA patients needed some level of emotional 
and physical care, they underestimated how much physical and 
emotional care was required, compared to carers and patients. The 
role of carers is described further in Table S1, with patient, carer 
and rheumatologist perspectives on the role of the carer expanded 
in Table S2. 
"She is fiercely independent and if I say, “I will help 
you”, “no, no, it is fine, I can do it”, even though some-
times she is struggling.” 
(Carer of sever patient, Australia)
“The carer is more for emotional support for mild and 
moderate patients… [O]nly the very severe type pa-
tients will require daily carer assistance...” 
(Rheumatologist, China)
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3.1.2 | Carer involvement in consultations
During initial and ongoing management consultations, rheumatolo-
gists considered carers were more likely to be present for severe 
patients followed by moderate and then mild patients. The behavior 
and attitude of rheumatologists toward carers was highly variable. 
Many carers stated strongly that their input, if/when taken into ac-
count by the rheumatologist during consultations, significantly im-
proves treatment decision-making and patient outcomes. However, 
some carers were frustrated as their role in caring for the patient 
and possible contributions in treatment decision-making were not 
adequately recognized by rheumatologists.
“They [carers] enhance communication with doctors, 
help to supervise the patient and implement my med-
ical advice.” 
(Rheumatologist, China)
“I basically talk only to the patient unless they have 
mostly no judgment ability, which is rare in cases of 
RA.” 
(Rheumatologist, Japan)
“Usually resented. They [doctors] like to tell you what 
the answer is but they don’t have to live with it…we 
have to put with whatever their solution they choose, 
we have to cope with that.” 
(Carer of severe patient, Australia)
3.1.3 | Carer support
Typically, one main primary carer provided most of the care for each 
RA patient. All carers of severe patients and some carers of moder-
ate patients admitted to experiencing repeated bouts of depression 
and physical exhaustion themselves.
“I’m very stressed. Taking care of a patient.” 
(Carer of moderate patient, China)
“I get very tired. I have just gone through a period of 
a few weeks where I didn’t want to get out of bed in 
the morning.” 
(Carer of severe patient, Australia)
3.2 | Quantitative
3.2.1 | Stakeholder demographics
A total of 131 rheumatologists, 382 patients and 395 carers partici-
pated in the study. Table 1 displays the baseline characteristics of 
respondents from each country. Rheumatologists in the Japanese 
sample were on average more experienced than those in the 
Chinese and Australian sample (17.3 mean years in practice vs 12.5 
and 11.3 years, respectively). The proportion of female rheumatolo-
gists was below 50% in all 3 countries, and the lowest in Japan (45%, 
35% and 10% female in China, Australia and Japan, respectively).
The duration since RA diagnosis was longest in Japan and short-
est in China (11.3 years vs 3.9 years, respectively). A majority of 
TA B L E  1   Quantitative study demographics
Australia China Japan
Rheumatologists (n) 49 42 40
Gender (% female) 35% 45% 10%
Mean y in practice 
(SD)
11.3 (5.1) 12.5 (3.3) 17.3 (6.6)
Patients (n) 112 110 160
Gender (% female) 63% 56% 55%
Mean age in y (SD) 54.6 (15.3) 43.6 (11.5) 55.9 (12.6)
Severity
Mild 44% 45% 83%
Moderate 41% 52% 15%
Severe 15% 3% 2%
Disease activity
Stable 76% 84% 96%
Progressive 24% 16% 4%
Mean duration 
since RA diagnosis 
in y (SD)
8.5 (6.4) 3.9 (3.5) 11.3 (5.9)
Status of carera 
Paidb  21% 71% 8%
Unpaid 64% 19% 88%
Mix of paid and 
unpaid
14% 10% 4%
Carers (n) 122 122 151
Gender (% female) 48% 65% 29%
Mean age in y 45.5 (14.2) 35.8 (9.6) 54.7 (13.4)
Severity (of RA patient cared for)
Mild 23% 25% 56%
Moderate 57% 59% 33%
Severe 20% 16% 11%
Mean duration 
caring for patient 
with RA in y (SD)
6.4 (5.5) 5.2 (3.5) 7.5 (5.6)
Status of carera 
Paidb  32% 56% 11%
Unpaid 58% 40% 85%
Mix of paid and 
unpaid
10% 4% 5%
Abbreviation: RA, rheumatoid arthritis
aPatients and carers were not recruited in dyads. 
bBased on response to the question of whether the carer was paid to 
provide care for the patient with RA. 
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the patients self-reported their RA severity as mild or moderate in 
Australia and China. However, in Japan, 83% self-reported their RA 
severity as mild and only 15% as moderate. Australia had the largest 
proportion of patients self-reporting severe disease (15% vs 3% in 
China and 2% in Japan). The majority of the patients in Japan had 
stable disease, followed by China and Australia (96%, 84% and 76%, 
respectively).
Carers in China were predominantly female whereas those in 
Japan were predominantly male (65% vs 29% female, respectively). 
Additionally, carers in China were on average younger than carers 
in Japan and Australia (35.8 years vs 54.7 and 45.5 years, respec-
tively). A greater proportion of carers in China were paid, compared 
to carers in Japan and Australia (56% vs 11% and 32%, respectively).
A separate descriptive analysis of moderate-to-severe patients 
and their carers was conducted to better understand the role of the 
carer in this subgroup. Within this group (150 patients and 252 car-
ers), 71% of patients self-reported their disease as stable and 29% 
as progressive. Among severe patients, 48% described their disease 
as progressive. In a country-specific analysis of moderate-to-severe 
patients, 93% of patients in Japan self-reported their disease 
as stable, compared with 72% and 60% in China and Australia, 
respectively.
3.2.2 | Role of the carer
Carers reported providing the following health and treatment sup-
port to the patients they cared for: reminders to take medication; 
monitoring medication intake; recognizing patient's physical and 
emotional state; recognizing when the patient is not being truthful 
when describing their condition to the doctor; recognizing when a 
change in medication or treatment is needed; understanding treat-
ment options; interpreting advice from the rheumatologist; and sug-
gesting alternative treatments based on own research that have not 
been provided by rheumatologist. The majority of carers (76%) pro-
vided reminders to take medication; this was highest in China (96%), 
followed by Australia (75%), and lowest in Japan (62%). Reminders 
to take medication were slightly higher in the moderate-to-severe 
F I G U R E  1   Estimates of level of support provided by the carer, received by patient and estimated by rheumatologist across all assessed 
domains. Patients were classified as mild, moderate or severe based on self-assessments. A, Level of physical support (such as help with 
personal care like washing hair, mobility such as assistance with moving around the house, meal preparation, transportation, household 
cleaning and cooking, shopping and buying groceries, etc). B, Level of health and treatment support (such as researching or discussing 
treatment options, arranging or giving medications, planning for medical appointments, reminding, encouraging and supporting the 
rheumatoid arthritis (RA) patient to take a medication or follow a prescribed treatment). C, Level of emotional support (such as reassuring 
and calming the RA patient if they feel distressed, providing support through events the RA patient is worried about, motivating and 
assisting the RA patient to reframe thoughts in a positive manner, etc). D, Level of financial support (such as providing household income, 
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subgroup (83%); highest in China (97%), followed by Australia (76%) 
and Japan (73%).
Overall, stakeholder estimates of level of physical, health and 
treatment, emotional and financial support provided by the carer 
tended to increase as disease severity increased. Carers consistently 
estimated the level and importance of the support they provide to 
be higher across physical, health and treatment, and emotional do-
mains, compared to the level of support patients said they received 
(Figure 1). Estimates of time spent providing support was higher for 
carers compared with patients for every domain measured.
Rheumatologists consistently overestimated the level of sup-
port provided by the carer, compared with the estimates from car-
ers and patients. However, estimates of level of physical support 
provided were high across all stakeholders. The support provided 
by carers was deemed “quite important” or “very important” by at 
least 1 in 2 rheumatologists. Rheumatologists considered health 
and treatment support to be the most important type of support 
provided by carers of moderate-to-severe patients. On the other 
hand, patients with moderate-to-severe disease and their carers 
considered physical support to be the most important. In terms of 
financial support for patients with severe RA, rheumatologists in 
Japan and China estimated higher required levels of financial sup-
port than those in Australia (60% in both China and Japan vs 45% 
in Australia). While patients with severe RA in Australia and Japan 
reflected the views of rheumatologists in those countries (35% and 
67%, respectively), patients in China were even more reliant on 
their carers for financial support (100%) than estimated by rheu-
matologists in China.
3.2.3 | Carer influence on treatment decision-
making
Active participation of carers in clinical consultations and treatment 
decision-making was considered important by most of the patients 
and carers (Table 2). Patients and carers in Australia and China 
TA B L E  2   Carer's influence on treatment decision-making
Country Rheumatoid arthritis severity
Australia China Japan Mild Moderate Severe
Patient N = 112 N = 110 N = 160 N = 232 N = 127 N = 23
Experienced anxiety at initial diagnosis 69% 88% 84% 78% 85% 83%
Believed education on all treatments at diagnosis 
would help to reduce anxiety
51% 87% 39% 47% 73% 57%
Educated on all treatment options:
At initial diagnosis 55% 28% 31% 56% 54% 39%
For ongoing management 37% 17% 16% 69% 73% 78%
Agree carer participation in clinical consultations 
and treatment decision-making is important
58% 93% 27% 41% 78% 65%
Rheumatologist n = 49 n = 42 n = 40 - - -
Agree education on all available treatments at 
diagnosis would help to lower anxiety
96% 95% 70% - - -
Discuss all available treatment options:
At initial diagnosis 96% 69% 85% - - -
For ongoing management 92% 84% 80% - - -
Agree carers play a role in treatment decision-making:
For mild patients 88% 83% 72% - - -
For moderate patients 100% 93% 75% - - -
For severe patients 100% 95% 77% - - -
Frequently solicited input from carer when they 
were present
98% 100% 95% - - -
Carer n = 122 n = 122 n = 151 n = 143 n = 191 n = 61
Agree carer participation in clinical consultations 
and treatment decision-making is important
81% 95% 52% 69% 89% 95%
Reported influencing treatment decisions for the 
patient they care for
61% 89% 58% 59% 72% 80%
Perceived carer input in treatment decisions to be 
important
81% 95% 52% 61% 83% 78%
Believed rheumatologists valued their input 80% 94% 79% 80% 85% 92%
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placed greater importance on active carer participation than those 
from Japan. Patients reported carers could potentially help them to 
discuss treatment options with their rheumatologist, understand the 
importance of taking medications as recommended, provide reas-
surance regarding the treatment, understand how to take their med-
ications correctly and help the rheumatologist to better understand 
their condition.
The vast majority of patients reported experiencing anxiety at 
the time of their diagnosis. More than half of all patients believed 
education on all available treatments would have helped to reduce 
the anxiety of being diagnosed with RA; however, this belief was 
more common in China than in Australia and Japan.
The majority of the rheumatologists agreed education on all 
available treatment options at the point of diagnosis may help lower 
anxiety of being diagnosed with a chronic condition. However, 28% 
of rheumatologists from Japan were not sure if this would be helpful 
(compared to 2% in both China and Australia). In current practice, 
more than 80% of rheumatologists reported discussing all available 
treatments at initial RA diagnosis as well as for ongoing RA manage-
ment. However, 37% of all patients said they were not educated on 
treatment options available at initial diagnosis, and 23% for ongoing 
RA management. In the moderate-to-severe subgroup, over half of 
the patients reported not being educated on all treatment options at 
initial diagnosis and a quarter for ongoing RA management.
More than half of all carers said they had influenced treat-
ment decisions for the patient they care for (Table 3). On the other 
hand, almost half of the carers in Japan (48%) believed their input 
in treatment decision-making was not very important, compared 
with 19% in Australia and 5% in China. The majority of the carers 
believed the rheumatologists valued their input as a carer. In the 
moderate-to-severe subgroup, 76% of patients considered the car-
er's input in treatment decision-making to be important: 93% in 
China, 81% in Australia and 48% in Japan. The majority of carers 
of moderate-to-severe patients considered their input in treatment 
decision-making to be important: 98% in China, 84% in Australia and 
57% in Japan. In addition, the majority of carers reported influencing 
treatment decisions for the moderate-to-severe patients they cared 
for: 91% in China, 69% in Japan and 62% in Australia. The highest 
levels of influence were reported by carers of patients with severe 
disease (80%). The majority of carers for this subgroup (87%) be-
lieved the rheumatologist valued their input as a carer.
From the rheumatologists’ perspective, 98% reported soliciting 
input from the carer when they were present. According to rheuma-
tologists in China, carer attendance increased as the disease sever-
ity increased. However, in Japan and Australia, higher attendance 
was reported for moderate than severe patients. The majority of 
the rheumatologists in Australia and China believed carers played a 
role in treatment decision-making for moderate and severe patients. 
However, almost a quarter of the rheumatologists in Japan consid-
ered carers had no influence in treatment decision-making for mod-
erate and severe patients.
3.2.4 | Impact of carer observations
All stakeholders believed carer observations on the physical and 
emotional wellbeing of the patient could be valuable. Among the 
patients, 95% in China, 65% in Australia and 38% in Japan sug-
gested these observations would be useful to their rheumatolo-
gists in managing their RA. Within the carer cohort, 99% of carers 
in China, 91% in Australia and 72% in Japan suggested these 
observations would be useful to the rheumatologist. Within the 
rheumatologist cohort, 100% of rheumatologists in Australia, 98% 
in China and 83% in Japan said these observations would be use-
ful to them for managing the patient. In the moderate-to-severe 
subgroup, 94% of rheumatologists, 92% of carers and 78% of pa-
tients agreed carer observations of the patient's physical and emo-
tional condition would be useful to the rheumatologist. However, 
TA B L E  3   Decisions influenced by carers
Treatment decision-making













Start a treatment regimen 26% 32% 35% 35% 31% 43%
Choose 1 treatment over another 29% 35% 26% 32% 38% 37%
Consider alternative treatment options 18% 30% 26% 29% 31% 39%
Follow the doctor's recommended treatment 
regimen
42% 56% 61% 38% 45% 55%
Stop following the doctor's recommended treatment 
regimen
10% 17% 26% 26% 28% 35%
F I G U R E  2   Potentially useful carer observations for clinical management. A, Carer observations that rheumatologists believed would be 
most useful in the assessment and management of rheumatoid arthritis patients. B, Carer observations patients were comfortable for their 
carer to share with their rheumatologist while in the consultation room with them. C, Observations the carers were comfortable sharing with 
the rheumatologist about the patient they care for
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None of the above
RA paent’s level of pain
RA paent’s level of mobility
Assessment of whether the RA paent’s treatment is working
RA paent’s recent mood
RA paent’s a­tudes towards treatment
Assessment of whether the RA paent is taking more medicaon than
usual to manage symptoms such as pain
RA paent’s recent emoonal state
RA paent’s level of adherence to treatment
RA paent’s ability to perform acvies of daily living
Japan China Australia
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Assessment of whether the RA paent is taking more
medicaon than usual to manage symptoms such as…
RA paent’s recent emoonal state
RA paent’s level of adherence to treatment
RA paent’s ability to perform acvies of daily living
Japan China Australia
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None of the above
RA paent’s level of pain
RA paent’s level of mobility
Assessment of whether the RA paent’s treatment is 
working
RA paent’s recent mood
RA paent’s a­tudes towards treatment
Assessment of whether the RA paent is taking more
medicaon than usual to manage symptoms such as…
RA paent’s recent emoonal state
RA paent’s level of adherence to treatment
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41% of patients in Japan, 17% in Australia and 2% in China were 
unsure. From the rheumatologists’ perspective, the top 3 most 
useful carer observations were the patient's ability to perform ac-
tivities of daily living, patient's level of adherence to treatment 
and the patient's recent emotional state. Both patients’ and carers’ 
comfort levels for these carer observations to be shared with the 
rheumatologist were moderately high (Figure 2). However, 55% of 
patients in Japan were not comfortable with carers sharing any 
observations outlined in the study questionnaire. Overall, 44% of 
all patients who were uncomfortable with carers sharing any ob-
servations had mild disease, 6% had moderate and 17% had severe 
disease.
Carer observations may also bring a new perspective to the con-
sultation room. The perception of disease severity differed between 
carers and patients. More carers described the patient they were 
caring for as moderate or severe, compared to patients’ self-descrip-
tions in each country.
3.2.5 | Support for carers
A quarter of all carers stated they did not receive enough support 
in their capacity as a carer while 18% of patients (34% unsure) and 
16% of rheumatologists (21% unsure) believed carers did not receive 
enough support. The type of support carers considered they needed 
varied between countries (Figure 3). The majority of the carers pre-
ferred to receive support and information from the rheumatologist. 
The top places where carers sought information were the internet 
and the rheumatologist's practice.
4  | DISCUSSION
This sequential mixed methods study aimed to understand the po-
tential impact of carer involvement on patients with RA and the role 
of carers in clinical management of RA.
Carers in the study reported providing a range of health and 
treatment support to the patients they cared for. However, carers 
consistently estimated the level and importance of their support to 
be higher, compared with the support patients reported receiving. 
This suggests patients may be underestimating the level of care they 
require or are receiving. It is possible that patient appreciation of 
carer support increases as disease severity progresses. This was re-
flected in the study findings as all stakeholder estimates of level of 
physical, health and treatment, emotional and financial support pro-
vided by the carer tended to increase as disease severity increased. 
It should be noted patients, carers and rheumatologists were not 
recruited in triads due to privacy issues. It is possible our sample 
included a greater proportion of carers of severe patients.
At least 1 in 2 rheumatologists estimated RA patients required 
moderate to high levels of support from their carer, regardless of 
level of disease severity (with the exception of physical support pro-
vided by carers of mild patients). For moderate-to-severe patients, 
stakeholders placed different levels of importance on the types of 
support provided by the carer. Rheumatologists considered health 
and treatment support to be the most important, whereas patients 
and carers deemed physical support as the most important.
Rheumatologists in Japan and China estimated higher required 
levels of financial support for patients with severe RA than those 
in Australia. Interestingly, patients with severe RA in Australia and 
Japan reflected the views of rheumatologists, while patients in China 
were even more reliant on their carers for financial support than es-
timated by rheumatologists. This may be a reflection of the expected 
financial burden in these countries. In Australia, the Pharmaceutical 
Benefits Scheme provides universal coverage of subsidized med-
icines for Australian residents with a fixed patient co-payment.18 
Japan also has coverage for all Japanese citizens via the National 
Health Insurance Scheme with patient co-payment ranging from 
0% to 30% depending on the age and employment status of the pa-
tient. In contrast, China's Basic Health Insurance Scheme (BHIS) only 
provides basic drug coverage within a cost-containment setting.18,19 
However, reforms are currently being undertaken to reimburse more 
costly medicines with the aim of reducing out-of-pocket costs for 
patients in China.20
The majority of rheumatologists believed carers played an im-
portant role in RA management and reported soliciting information 
from the carer if they were present. The highest perceived values 
for carer input across all 3 stakeholder groups were seen in China, 
followed by Australia and then Japan. Patients reported carers 
could potentially help them to discuss treatment options with their 
rheumatologist, understand the importance of taking medications 
as recommended, provide reassurance regarding the treatment, 
understand how to take their medications correctly and help the 
rheumatologist to better understand their condition. These findings 
were reflected in the moderate-to-severe subgroup. The high value 
of carer input in China may be due to Chinese culture recognizing 
the high involvement of carers (ie accepting caregiving as part of 
life), which may then flow on into clinical practice.21,22 In Australia, 
a majority of rheumatologists and carers agreed carer observations 
contributed to RA management; however, only 63% of patients held 
this view. This may be due to Australian culture and clinical prac-
tice placing emphasis on independence and ownership of the dis-
ease.23,24 In contrast, almost a quarter of rheumatologists in Japan 
believed carers did not influence treatment decision-making for 
moderate and severe patients. Patients in Japan were also less likely 
to believe carer observations could contribute to their RA manage-
ment than in China and Australia. A majority of the patients in the 
Japanese sample were between the ages of 18 and 50, which may 
have contributed to this. Younger patients are more likely than older 
patients to express their views and take an active part in treatment 
decision-making.25 Furthermore, a larger proportion of the patients 
in the Japanese sample had mild and stable disease, compared to 
Australia and China, suggesting they may have required less carer 
input. Japanese culture also emphasizes traditional clinician-cen-
tered practice where patients rely on the clinician to make decisions 
about their treatment.26
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Rheumatologists identified the following carer observations 
as useful: patient's ability to perform activities of daily living, pa-
tient's level of adherence to treatment and patient's recent emo-
tional state. Both patients’ and carers’ comfort levels for these 
carer observations to be shared with the rheumatologist were 
moderately high. Patients from Australia were most comfortable 
with carers sharing observations relating to level of mobility, pain, 
and ability to perform activities of daily living, and least comfort-
able with observations of medication frequency and attitudes to-
ward treatment. In China, patients were most comfortable with 
carers sharing observations of ability to perform activities of daily 
living, assessment of whether the treatment is working and recent 
mood, and least comfortable with observations of level of mo-
bility. Patients from Japan were generally less comfortable with 
carers sharing observations than Australia and China, with 55% 
of patients not comfortable with any observations being shared. 
However, overall analysis showed 44% of all patients who were 
uncomfortable with carers sharing any observations had mild dis-
ease. Since 83% of the patients in the Japanese sample had mild 
disease, it may have influenced the finding. The large variation in 
patient and carer comfort levels for sharing observations seen in 
this study suggests a need to consider cultural sensitivities and 
values when gathering carer-reported outcomes.
Carers may also bring a new perspective to the consultation. In 
all 3 countries, more carers described the patient they were caring 
for as moderate or severe, compared to patient's self-description. 
However, patients and carers were not recruited in dyads. Despite 
this limitation, the data may suggest patients could be understat-
ing the severity of their symptoms. This is in line with a previous 
study, which found health status ratings given by carers were higher 
than those recorded by the patients themselves.8 However, 47.5% of 
carers in the study reported mild-to-moderate burden of caregiving, 
suggesting carer perception of health status of the patient may be 
proportional to the level of caregiving burden.8
Involving a carer during consultations may also help to alleviate 
some of the anxiety experienced by patients. On average, 80% of 
patients experienced anxiety at the time of their diagnosis. The pro-
portion of patients experiencing anxiety was higher in China com-
pared with Australia and Japan. The increased anxiety expressed 
by patients in China may be a reflection of the expected financial 
burden. In addition, the Chinese sample had a lower mean age and 
shorter duration of disease than the Australian and Japanese sam-
ples, suggesting they were more likely to be employed or require 
employment, potentially contributing to their anxiety.
In addition, more patients in China believed anxiety would have 
been improved if they were educated on all available treatments 
F I G U R E  3   Types of support carers would like to receive in each country
0% 10% 20% 30% 40% 50% 60%
Support that helps the carer to manage the emoonal
burden of caring for an RA paent
Support that enables the RA paent to enjoy social and
community acvies independently of their carers
Supports aimed at increasing the sustainability of family 
caring arrangement, including personal care and 
domesc assistance related to the RA paent’s disability
Support that increases the RA paent’s independence
Family support and counselling due to the RA paent’s 
disease
Building the skills and capacity of other family members 
to manage the impact of the RA paent’s disease on 
family life
None of the above
Australia China Japan
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at the time of diagnosis, compared with Australia and Japan. This 
knowledge could provide patients and their carers with some reas-
surance on what to expect and how to plan for the future. A major-
ity of rheumatologists agreed providing this knowledge at the point 
of diagnosis could help lower anxiety of being diagnosed. However, 
28% of rheumatologists from Japan were not sure if this was the 
case (compared to 2% in both China and Australia). This may be a 
direct reflection of patient expectations as only 39% of patients in 
Japan believed knowledge of all treatments would help to lower anx-
iety at the time of diagnosis.
Interestingly, despite a majority of the rheumatologists re-
porting provision of this information, 37% of all patients said they 
were not educated on all the treatment options at initial diagno-
sis and 23% for ongoing RA management. In the moderate-to-se-
vere patient group, the gap was even more pronounced with over 
half the patients reporting not being educated on all treatment 
options at initial diagnosis. This disconnect between patient-re-
ported and rheumatologist-reported provision of education may 
reflect the patients’ unmet expectation of education and/or their 
failure to understand the information provided. A number of fac-
tors could affect a patient's ability to absorb the information pro-
vided, including anxiety associated with being diagnosed, how the 
information is delivered, use of difficult medical terminology, and 
so on.27
Carers’ influence on treatment was not limited to continuing 
treatments as prescribed. Patients and their carers reported carers 
could influence patients to stop prescribed treatments or consider 
other treatment options as well. As such it is important to involve 
carers in the treatment decision-making process and provide edu-
cation so as to harness their influence to ensure the best outcomes.
All stakeholders agreed carers required some level of support. 
The impact of caring for an RA patient on both the mental and phys-
ical health of the carer has been previously documented.28-31 The 
type of support carers sought varied greatly from country to country 
and may be a reflection of the different cultures and value systems, 
or different carer demographics.
This study has several limitations. Since this was an exploratory 
study with a small sample size, only a descriptive analysis of the data 
was conducted to better understand patterns in carer involvement 
in each country. Due to privacy issues, it was also not possible to 
recruit triads of patients, carers and rheumatologists. Therefore, 
it was not possible to draw conclusions when comparing different 
perspectives. The majority of the carers in the study described the 
patient they were caring for as moderate or severe, limiting the 
applicability of the results to mild patients. In addition, the lack of 
validated carer-reported outcomes in rheumatology or for the care 
of RA patients specifically was a limitation. Consequently, there 
was a degree of overlap in definitions of potential carer-reported 
outcomes evaluated in the survey (ie, “recent mood” vs “emotional 
state”), which may have confounded the results on the most use-
ful carer-reported outcomes. In addition, “treatment” may have 
meant something different to patients and carers, compared to 
rheumatologists. For patients, treatment may have encompassed 
holistic management.
5  | CONCLUSION
This study investigated the roles and potential impact of carers in RA 
management in the Asia-Pacific region. Carers play an important role 
in RA management by providing physical, emotional and financial 
support to patients, especially for patients with moderate-to-severe 
disease. They may also help to optimize treatment outcomes by rein-
forcing important information about the disease and treatment, and 
providing observations that may help rheumatologists in treatment 
decision-making.
While stakeholders considered carer observations to be valu-
able, they were obtained on an ad hoc basis. Development of vali-
dated carer-reported outcomes and a framework for their routine 
collection would facilitate their inclusion in routine consultations. 
Validation would require correlation with PROs and other clinical 
measures, and assessment of their utility. Any impact on clinician 
decision-making by carer-reported measures will also require inves-
tigation and careful assessment of acceptability to all stakeholders 
in different settings. Finally, integration of carer-reported outcomes 
into clinical discussions should not interfere with workflow or add to 
the workload of rheumatologists.
ACKNOWLEDG EMENTS
Johnson & Johnson Pte. Ltd. sponsored the study, contributed 
to its design, and participated in the analysis, and interpreta-
tion of the data, and in the writing, reviewing, and approval of 
the final version. Data collection and analysis were performed 
by Blue Planet Research & Consulting Pty Ltd. (Petersham NSW 
2049, Australia). Medical writing was provided by Kajal Praveena 
Naidu on behalf of Huntsworths Health Pte Ltd. (Singapore 
048941, SG) and was funded by Johnson & Johnson Pte. Ltd. 
This manuscript was based on work previously presented at the 
2019 annual congress of the Asia-Pacific League of Associations 
for Rheumatology (APLAR) and has been published as a confer-
ence abstract.
CONFLIC T OF INTERE S T
K. Pile has received grants and personal fees from Janssen 
Pharmaceuticals. KA Gibson has received grants from Novartis 
and personal fees from Janssen and UCB. W. Favorito has received 
honoraria from Johnson and Johnson Services. R. Mu has received 
consulting fees from Xian Janssen and Johnson & Johnson Pte Ltd. 
outside the submitted work. H. Nahakara has received consult-
ing fees from Janssen Pharmaceutical; speaker fees from Chugai 
Pharmaceutical, Bristol-Myers Squibb, Mitsubishi Tanabe Pharma 
Corporation, Eisai Co. Ltd, UCB, and Abbvie; and has received patent 
royalties from Chugai Pharmaceutical. M. Kishimoto has received 
honoraria from Janssen. S. Hirata has received grants from AbbVie, 
     |  909PILE Et aL.
Ayumi, Eisai, Pfizer, Sanofi, Tanabe Mitsubishi; and personal fees 
from Jannsen, Abbvie, Asahi-Kasei Pharma, Asahi-Kasei Medical, 
Astellas, Ayumi, Celgene, Chugai, Eisai, Eli Lilly, Kissei, Novartis, 
Pfizer, Sanofi, Novartis, Takeda, Tanabe Mitsubishi and UCB. Y. 
Kaneko has received personal fees from Janssen, Abbvie, Astellas, 
Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hismitsu, Kissei, 
Pfizer, Sanofi, Takeda, Tanabe Mitsubishi, UCB and Kirin. LS Tam 
has received personal fees from Janssen, Abbvie, Lilly, Novartis, 
Celltrion and Sanofi. R. Norager, M. Skillecorn, P. Chen, B. Wahking 
and D. Furtner are employees of Johnson & Johnson Pte. Ltd. and 
may own stock/options. Y. Chen, S. Elderton, Z. Li and CS Lau have 
no conflicts of interest to declare.
AUTHOR CONTRIBUTIONS
All authors contributed equally to the conception and design of the 
study, analysis and interpretation of the data, and final approval of 
the version of the article to be published.
ORCID
Rachel Norager  https://orcid.org/0000-0002-0185-9736 
Kathryn A. Gibson  https://orcid.org/0000-0003-2331-0311 
Shintaro Hirata  https://orcid.org/0000-0002-2474-9943 
Lai-Shan Tam  https://orcid.org/0000-0001-6410-8852 
R E FE R E N C E S
 1. American College of Rheumatology, Association of Rheumatology 
Health Profesionals. Position statement: Interdisciplinary care for 
patients with rheumatic and musculoskeletal diseases by the rheu-
matology health care team. Available from: https://www.rheum 
atolo gy.org/Porta ls/0/Files /Multi disci plina ry%20Car e%20for 
%20Pat ients %20wit h%20Rhe umati c%20and %20Mus culos kelet 
al%20Dis ease.pdf (accessed November 2018)
 2. Felson DT, LaValley MP. The ACR20 and defining a threshold for 
response in rheumatic diseases: too much of a good thing. Arthritis 
Res Ther. 2014;16(1):101.
 3. Bitton A, Onega T, Tosteson A, et al. Toward a better understanding 
of patient-reported outcomes in clinical practice. Am J Manag Care. 
2014;20(4):281-283.
 4. Mercieca-Bebber R, King MT, Calvert MJ,, et al. The importance of 
patient-reported outcomes in clinical trials and strategies for future 
optimization. Patient Relat Outcome Meas. 2018;9:353-367.
 5. Wolpert M. Uses and abuses of patient reported outcome mea-
sures (PROMs): potential iatrogenic impact of PROMs imple-
mentation and how it can be mitigated. Adm Policy Ment Health. 
2014;41(2):141-145.
 6. Goldberg A, Rickler KS. The role of family caregivers for people 
with chronic illness. Med Health R I. 2011;94(2):41-42.
 7. Noonan MC, Wingham J, Taylor RS. 'Who Cares?' The experiences 
of caregivers of adults living with heart failure, chronic obstructive 
pulmonary disease and coronary artery disease: a mixed methods 
systematic review. BMJ Open. 2018;8(7):e020927.
 8. Bahlas S, Fathaldin O, Janoudi N, Almoallim H, Ibrahim A, Algohary 
S. Do rheumatoid arthritis patients rate their health status differ-
ent than their caregivers? Antiinflamm Antiallergy Agents Med Chem. 
2015;14(3):199-203.
 9. Prothero L, Georgopoulou S, Galloway J, Williams R, Bosworth A, 
Lempp H. Patients' and carers' views and expectations about inten-
sive management for moderate rheumatoid arthritis: a qualitative 
study. Psychol Health Med. 2016;21(8):918-925.
 10. Schoonenboom J, Johnson RB. How to construct a mixed methods 
research design. Kolner Z Soz Sozpsychol. 2017;69(Suppl 2):107-131.
 11. Australian Government National Health and Medical Research 
Council. Ethical considerations in quality assurance and evaluation 
activities, March 2014. Available from: https://www.nhmrc.gov.au/
about -us/resou rces/ethic al-consi derat ions-quali ty-assur ance-and-
evalu ation -activ ities (accessed 26 January 2020)
 12. Xinqing Z, Wenxia Z, Yandong Z. The Chinese ethical review system 
and its compliance mechanisms. Available from: http://trust -proje 
ct.eu/wp-conte nt/uploa ds/2016/03/Chine se-Ethic s-Revie w-Sys-
tem.pdf (accessed 26 January 2020).
 13. Waseda University Office of Research Ethics. Ethical guidelines for 
medical and health research involving human subjects. Available 
from: https://www.waseda.jp/inst/ore/en/proce dures /human / 
(accessed 26 January 2020)
 14. Alten R, van de Laar M, De Leonardis F, et al. Physical and emotional 
burden of rheumatoid arthritis: Data from RA matters, a Web-
based survey of patients and healthcare professionals. Rheumatol 
Ther. 2019;6(4):587-597.
 15. Gibofsky A, Galloway J, Kekow J, et al. Comparison of patient and 
physician perspectives in the management of rheumatoid arthritis: 
results from global physician- and patient-based surveys. Health 
Qual Life Outcomes. 2018;16(1):211.
 16. Thomas GP, Saunders CL, Roland MO, et al. Informal carers' 
health-related quality of life and patient experience in primary care: 
evidence from 195,364 carers in England responding to a national 
survey. BMC Fam Pract. 2015;16:62.
 17. Wang J, Zou X, Zhou L,, et al. Patient satisfaction after nurse-led 
care in Chinese patients with rheumatoid arthritis: A China study. 
Biomed Res. 2017;28(11):4972-4978.
 18. Cook G, Kim H From regulatory approval to subsidized patient 
access in the Asia-pacific region: a comparison of systems across 
Australia, China, Japan, Korea, New Zealand, Taiwan, and Thailand. 
Value Health Reg Issues. 2015;6:40-45.
 19. Xu C, Wang X, Mu R, et al. Societal costs of rheumatoid arthritis 
in China: a hospital-based cross-sectional study. Arthritis Care Res 
(Hoboken). 2014;66(4):523-531.
 20. World Health Organization. Expanding access to high quality med-
icines. Available from: https://www.who.int/china /activ ities /expan 
ding-acces s-to-high-quali ty-medic ines (accessed 03 February 
2020)
 21. Shea J, Zhang H. Introduction to aging and caregiving in Chinese 
populations. Ageing Int. 2017;42:137-141.
 22. Qiu X, Sit JWH, Koo FK. The influence of Chinese culture on fam-
ily caregivers of stroke survivors: A qualitative study. J Clin Nurs. 
2018;27(1–2):e309-e319.
 23. Vermaak V, Briffa NK, Langlands B, et al. Evaluation of a disease 
specific rheumatoid arthritis self-management education program, 
a single group repeated measures study. BMC Musculoskelet Disord. 
2015;16:214.
 24. The Royal Australian College of General Practitioners. Clinical 
guideline for the diagnosis and management of early rheumatoid 
arthritis, August 2009. Available from: https://www.racgp.org.
au/FSDED EV/media /docum ents/Clini cal%20Res ource s/Guide 
lines /Joint %20rep lacem ent/Clini cal-guide line-for-the-diagn osis-
and-manag ement -of-early -rheum atoid -arthr itis.pdf (accessed 
November 2018)
 25. Chilton F, Collett RA. Treatment choices, preferences and deci-
sion-making by patients with rheumatoid arthritis. Musculoskeletal 
Care. 2008;6(1):1-14.
 26. Aoki A, Ohbu S. Japanese physicians' preferences for decision 
making in rheumatoid arthritis treatment. Patient Prefer Adherence. 
2016;10:107-113.
 27. Kessels RP. Patients' memory for medical information. J R Soc Med. 
2003;96(5):219-222.
910  |     PILE Et aL.
 28. Brouwer WB, van Exel NJA, van de Berg B, et al. (2004) Burden 
of caregiving: evidence of objective burden, subjective burden, and 
quality of life impacts on informal caregivers of patients with rheu-
matoid arthritis. Arthritis Rheum. 2004;51(4):570-577.
 29. Chung SW, Ha YJ, Kang EH, et al. The psychosocial status of the 
family members of rheumatoid arthritis patients in Korea. Rheumatol 
Int. 2016;36(5):719-724.
 30. Jacobi CE. Dimension-specific burden of caregiving among part-
ners of rheumatoid arthritis patients. Rheumatology (Oxford). 
2003;42(10):1226-1233.
 31. Ru J, Ma J, Niu H, et al. Burden and depression in caregivers 
of patients with rheumatoid arthritis in China. Int J Rheum Dis 
2018;22(4):608-613.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
How to cite this article: Pile K, Norager R, Skillecorn M, et al. 
Elevating the role of carers in rheumatoid arthritis 
management in the Asia-Pacific region. Int J Rheum Dis. 
2020;23:898–910. https://doi.org/10.1111/1756-185X.13893
